レイクフロント・バイオセラピューティクス
Galapagos N.V. Sponsored ADR
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | 0.22 | $6M | -$83M |
| 2025 Q4 | 11.87 | $901M | -$49M |
| 2025 Q3 | -3.07 | $71M | -$65M |
| 2025 Q2 | -1.60 | $65M | -$113M |